Wall Street brokerages expect that Omeros Co. (NASDAQ:OMER) will report sales of $2.24 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Omeros’ earnings, with the lowest sales estimate coming in at $1.47 million and the highest estimate coming in at $3.00 million. Omeros reported sales of $12.26 million in the same quarter last year, which indicates a negative year over year growth rate of 81.7%. The firm is expected to announce its next quarterly earnings results on Wednesday, May 9th.
On average, analysts expect that Omeros will report full year sales of $2.24 million for the current year, with estimates ranging from $9.52 million to $86.71 million. For the next fiscal year, analysts anticipate that the firm will post sales of $25.26 million per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Omeros.
Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.03). The business had revenue of $13.76 million during the quarter, compared to analysts’ expectations of $21.94 million. The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.45) EPS.
A number of research analysts have commented on the company. Maxim Group set a $24.00 price objective on Omeros and gave the company a “buy” rating in a research report on Wednesday, January 3rd. HC Wainwright set a $30.00 price objective on Omeros and gave the company a “buy” rating in a research report on Thursday, December 14th. BidaskClub upgraded Omeros from a “strong sell” rating to a “sell” rating in a research report on Friday, March 23rd. ValuEngine upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Friday, March 23rd. Finally, Cantor Fitzgerald set a $19.00 price objective on Omeros and gave the company a “hold” rating in a research report on Thursday, March 1st. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. Omeros has a consensus rating of “Hold” and an average target price of $25.88.
OMER traded up $0.07 during mid-day trading on Tuesday, reaching $13.58. The stock had a trading volume of 1,311,249 shares, compared to its average volume of 1,822,332. The firm has a market capitalization of $655.72, a price-to-earnings ratio of -17.19 and a beta of 3.62. The company has a debt-to-equity ratio of -29.93, a quick ratio of 4.10 and a current ratio of 4.12. Omeros has a 52 week low of $8.36 and a 52 week high of $27.09.
Several hedge funds have recently bought and sold shares of OMER. Capital Analysts LLC lifted its stake in shares of Omeros by 885.6% in the 4th quarter. Capital Analysts LLC now owns 590,849 shares of the biopharmaceutical company’s stock valued at $36,125,000 after purchasing an additional 530,899 shares during the period. Ingalls & Snyder LLC lifted its stake in shares of Omeros by 3.4% in the 4th quarter. Ingalls & Snyder LLC now owns 5,335,239 shares of the biopharmaceutical company’s stock valued at $103,664,000 after purchasing an additional 174,204 shares during the period. First Trust Advisors LP acquired a new position in shares of Omeros in the 4th quarter valued at $2,057,000. Deutsche Bank AG raised its stake in Omeros by 120.8% during the 4th quarter. Deutsche Bank AG now owns 105,909 shares of the biopharmaceutical company’s stock worth $2,057,000 after buying an additional 57,945 shares during the period. Finally, Virtus Fund Advisers LLC acquired a new stake in Omeros during the 4th quarter worth $973,000. 48.56% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “$2.24 Million in Sales Expected for Omeros Co. (OMER) This Quarter” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/04/15/2-24-million-in-sales-expected-for-omeros-co-omer-this-quarter.html.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.